Analyzing IBS to Identify Biomarkers and Microbiome Signatures

Completed · Not applicable

Conditions studied: Diarrhoea Predominant Irritable Bowel Syndrome, IBS

In brief

Microbiota from fecal samples from IBS-D patients, in combination with vitamin D supplementation added to our 3-D immunocompetent intestinal models will establish a high fidelity disease model to achieve our long-term goal to understand the relationship between gut microbiome, vitamin D levels, host gene expression and IBS-D symptoms that could ultimately be used as a testing platform for treatment and prevention.

Key facts

Study ID

NCT02419963

Run by

Mayo Clinic

People needed

26

Starts

2015-05-01

Expected to finish

2016-12-12

Last updated by the study team

2017-07-07

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• IBS-D subjects:
• Patients who fulfill IBS-D criteria, without causes of active inflammation.
• active symptoms for at least 2 months
• diagnosed at least 6 months prior to enrollment
• Healthy Control:
• Healthy control patients should have no active infection or inflammation.

You may not qualify if…

• does not meet inclusion criteria
• will not participate in blood draw, stool sample donation, or endoscopy
• history of acute illness within 3 months of testing
• any fecal transplant history

Where it is running

• Mayo Clinic in Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.